1. Home
  2. MGNX vs CMCM Comparison

MGNX vs CMCM Comparison

Compare MGNX & CMCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGNX
  • CMCM
  • Stock Information
  • Founded
  • MGNX 2000
  • CMCM 2009
  • Country
  • MGNX United States
  • CMCM China
  • Employees
  • MGNX N/A
  • CMCM N/A
  • Industry
  • MGNX Biotechnology: Pharmaceutical Preparations
  • CMCM Computer Software: Prepackaged Software
  • Sector
  • MGNX Health Care
  • CMCM Technology
  • Exchange
  • MGNX Nasdaq
  • CMCM Nasdaq
  • Market Cap
  • MGNX 114.2M
  • CMCM 115.1M
  • IPO Year
  • MGNX 2013
  • CMCM 2014
  • Fundamental
  • Price
  • MGNX $1.66
  • CMCM $4.90
  • Analyst Decision
  • MGNX Hold
  • CMCM
  • Analyst Count
  • MGNX 9
  • CMCM 0
  • Target Price
  • MGNX $5.33
  • CMCM N/A
  • AVG Volume (30 Days)
  • MGNX 770.0K
  • CMCM 56.0K
  • Earning Date
  • MGNX 08-12-2025
  • CMCM 09-12-2025
  • Dividend Yield
  • MGNX N/A
  • CMCM N/A
  • EPS Growth
  • MGNX N/A
  • CMCM N/A
  • EPS
  • MGNX N/A
  • CMCM N/A
  • Revenue
  • MGNX $154,050,000.00
  • CMCM $120,663,543.00
  • Revenue This Year
  • MGNX N/A
  • CMCM $14.27
  • Revenue Next Year
  • MGNX N/A
  • CMCM $39.26
  • P/E Ratio
  • MGNX N/A
  • CMCM N/A
  • Revenue Growth
  • MGNX 255.31
  • CMCM 27.02
  • 52 Week Low
  • MGNX $0.99
  • CMCM $3.02
  • 52 Week High
  • MGNX $5.10
  • CMCM $6.77
  • Technical
  • Relative Strength Index (RSI)
  • MGNX 51.94
  • CMCM 47.99
  • Support Level
  • MGNX $1.47
  • CMCM $5.55
  • Resistance Level
  • MGNX $1.64
  • CMCM $6.62
  • Average True Range (ATR)
  • MGNX 0.12
  • CMCM 0.44
  • MACD
  • MGNX -0.00
  • CMCM -0.07
  • Stochastic Oscillator
  • MGNX 26.83
  • CMCM 6.17

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About CMCM Cheetah Mobile Inc. each representing fifty (50)

Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.

Share on Social Networks: